-
公开(公告)号：US11351168B1
公开(公告)日：2022-06-07
申请号：US16825285
申请日：2020-03-20
Applicant: Celgene CAR LLC
Inventor： Juswinder Singh , Russell C. Petter , Richland Wayne Tester , Arthur F. Kluge , Hormoz Mazdiyasni , William Frederick Westlin, III , Deqiang Niu , Lixin Qiao
IPC: C07D239/30 , A61K31/505 , C07D495/04 , C07D239/48 , C07D401/14 , C07D403/12 , C07D407/12 , C07D413/12 , C07D413/14 , C07D471/04 , C07D487/04 , C07D487/18 , A61K31/506 , A61K31/519 , A61K31/5377 , A61K31/538 , A61K31/541 , A61K45/06 , C07D401/12 , C07D405/12 , C07D405/14 , C07D487/08 , C07D239/47
Abstract: The present invention provides 2,4-disubstituted pyrimidine compounds useful as kinase inhibitors, pharmaceutically acceptable compositions thereof, and methods of using the same.
-
公开(公告)号：US20210017137A1
公开(公告)日：2021-01-21
申请号：US16797776
申请日：2020-02-21
Applicant: Celgene CAR LLC
Inventor： Mei Lai , Steven Richard Witowski , Richland Wayne Tester , Kwangho Lee
IPC: C07D239/48 , C07C55/02 , C07C55/07 , C07C62/02 , C07C309/04 , C07C309/05 , C07C309/27 , C07C309/29 , C07C309/30 , C07C309/35
Abstract: The present invention provides a salt form and compositions thereof, which are useful as an inhibitor of EGFR kinases and which exhibits desirable characteristics for the same.
-
公开(公告)号：US20170217904A1
公开(公告)日：2017-08-03
申请号：US15401637
申请日：2017-01-09
Applicant: Celgene CAR LLC
Inventor： Mei Lai , Steven Richard Witowski , Richland Wayne Tester , Kwangho Lee
IPC: C07D239/48 , C07C309/27 , C07C309/05 , C07C62/02 , C07C309/04 , C07C309/35 , C07C55/07 , C07C309/30 , C07C309/29 , C07C55/02
CPC classification number: C07D239/48 , C07B2200/13 , C07C55/02 , C07C55/07 , C07C62/02 , C07C309/04 , C07C309/05 , C07C309/27 , C07C309/29 , C07C309/30 , C07C309/35
Abstract: The present invention provides a salt form and compositions thereof, which are useful as an inhibitor of EGFR kinases and which exhibits desirable characteristics for the same.
-
公开(公告)号：US10828300B2
公开(公告)日：2020-11-10
申请号：US15996162
申请日：2018-06-01
Applicant: Celgene CAR LLC
Inventor： Juswinder Singh , Russell C. Petter , Richland Wayne Tester , Arthur F. Kluge , Hormoz Mazdiyasni , William Frederick Westlin, III , Deqiang Niu , Lixin Qiao
IPC: C07D239/48 , A61K31/505 , C07D239/47 , C07D401/14 , C07D403/12 , C07D407/12 , C07D413/12 , C07D413/14 , C07D471/04 , C07D487/04 , C07D487/18 , C07D401/12 , C07D417/14 , A61K31/506 , A61K31/5377
Abstract: The present invention provides 2,4-diaminopyrimidines, and/or pharmaceutically acceptable compositions thereof, as kinase inhibitors.
-
公开(公告)号：US20190192512A1
公开(公告)日：2019-06-27
申请号：US16024514
申请日：2018-06-29
Applicant: Celgene CAR LLC
Inventor： Juswinder Singh , Russell C. Petter , Richland Wayne Tester , Arthur F. Kluge , Hormoz Mazdiyasni , William Frederick Westlin, III , Deqiang Niu , Lixin Qiao
IPC: A61K31/505 , A61K31/541 , C07D239/47 , A61K31/506 , A61K31/519 , A61K31/5377 , A61K31/538 , C07D487/08 , A61K45/06 , C07D401/12 , C07D405/12 , C07D405/14 , C07D487/18 , C07D487/04 , C07D471/04 , C07D413/14 , C07D413/12 , C07D407/12 , C07D403/12 , C07D401/14 , C07D239/48 , C07D495/04
Abstract: The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.
-
Patent Agency Ranking
公开(公告)号：US09987276B2
公开(公告)日：2018-06-05
申请号：US15080351
申请日：2016-03-24
Applicant: Celgene CAR LLC
Inventor： Juswinder Singh , Russell C. Petter , Richland Wayne Tester , Arthur F. Kluge , Hormoz Mazdiyasni , William Frederick Westlin, III , Deqiang Niu , Lixin Qiao
IPC: C07D239/48 , A61K31/505 , C07D239/47 , C07D401/14 , C07D403/12 , C07D407/12 , C07D413/12 , C07D413/14 , C07D471/04 , C07D487/04 , C07D487/18 , C07D401/12 , C07D417/14 , A61K31/506 , A61K31/5377
CPC classification number: A61K31/505 , A61K31/506 , A61K31/5377 , C07D239/47 , C07D239/48 , C07D401/12 , C07D401/14 , C07D403/12 , C07D407/12 , C07D413/12 , C07D413/14 , C07D417/14 , C07D471/04 , C07D487/04 , C07D487/18
Abstract: The present invention provides 2,4-diaminopyrimidines, and/or pharmaceutically acceptable compositions thereof, as kinase inhibitors.
-
公开(公告)号：US11292772B2
公开(公告)日：2022-04-05
申请号：US16797776
申请日：2020-02-21
Applicant: Celgene CAR LLC
Inventor： Mei Lai , Steven Richard Witowski , Richland Wayne Tester , Kwangho Lee
IPC: C07D239/48 , C07C55/02 , C07C55/07 , C07C62/02 , C07C309/04 , C07C309/05 , C07C309/27 , C07C309/29 , C07C309/30 , C07C309/35
Abstract: The present invention provides a salt form and compositions thereof, which are useful as an inhibitor of EGFR kinases and which exhibits desirable characteristics for the same.
-
公开(公告)号：US10596172B2
公开(公告)日：2020-03-24
申请号：US16024514
申请日：2018-06-29
Applicant: Celgene CAR LLC
Inventor： Juswinder Singh , Russell C. Petter , Richland Wayne Tester , Arthur F. Kluge , Hormoz Mazdiyasni , William Frederick Westlin, III , Deqiang Niu , Lixin Qiao
IPC: C07D239/48 , A61K31/505 , C07D239/47 , C07D401/14 , C07D403/12 , C07D407/12 , C07D413/12 , C07D413/14 , C07D471/04 , C07D487/04 , C07D487/18 , A61K31/506 , A61K31/519 , A61K31/5377 , A61K31/538 , A61K31/541 , A61K45/06 , C07D401/12 , C07D405/12 , C07D405/14 , C07D487/08 , C07D495/04
Abstract: The present invention provides 2,4-disubstituted pyrimidine compounds useful as kinase inhibitors, pharmaceutically acceptable compositions thereof, and methods of using the same.
-
公开(公告)号：US10570099B2
公开(公告)日：2020-02-25
申请号：US16015626
申请日：2018-06-22
Applicant: Celgene CAR LLC
Inventor： Mei Lai , Steven Richard Witowski , Richland Wayne Tester , Kwangho Lee
IPC: C07D239/48 , C07C55/02 , C07C55/07 , C07C62/02 , C07C309/04 , C07C309/05 , C07C309/27 , C07C309/29 , C07C309/30 , C07C309/35
Abstract: The present invention provides a salt form and compositions thereof, which are useful as an inhibitor of EGFR kinases and which exhibits desirable characteristics for the same.
-
公开(公告)号：US20190152925A1
公开(公告)日：2019-05-23
申请号：US16015626
申请日：2018-06-22
Applicant: Celgene CAR LLC
Inventor： Mei Lai , Steven Richard Witowski , Richland Wayne Tester , Kwangho Lee
IPC: C07D239/48 , C07C309/04 , C07C62/02 , C07C55/02 , C07C55/07 , C07C309/30 , C07C309/35 , C07C309/05 , C07C309/27 , C07C309/29
Abstract: The present invention provides a salt form and compositions thereof, which are useful as an inhibitor of EGFR kinases and which exhibits desirable characteristics for the same.
-
-
-
-
-
-
-
-
-
Search Results
13
records
(took 0.031 seconds)
